Clinical trials · Washington, D.C., DC
Lung Cancer (NSCLC) clinical trials in Washington, D.C.
We’re tracking 157 recruiting lung cancer (nsclc) studies with a site in or near Washington, D.C. — including Phase 1, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06452277RecruitingPhase 3
Testing sevabertinib for advanced HER2-mutated lung cancer
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Baltimore, MarylandAges 18 years+ - NCT06731907RecruitingPhase 2
Keytruda with or without chemo for advanced lung cancer
This trial tests a new combination of drugs (Keytruda with or without chemotherapy) to see if it works better for advanced lung cancer. It's for people who haven't had immunotherapy or chemotherapy for their cancer that has spread.
Baltimore, MarylandAges 18 years+ - NCT04614103RecruitingPhase 2
Immune cell therapy for advanced lung cancer after chemotherapy
This trial studies LN-145, a treatment made from your own immune cells, for metastatic (stage IV) non-small-cell lung cancer. It may help shrink tumors after your cancer has progressed despite standard first-line chemotherapy and immunotherapy.
Baltimore, MarylandAges 18–70 - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Baltimore, MarylandAges 18 years+ - NCT07398209Recruiting
Motion management study for lung cancer patients having radiation
This study uses MRI scans to understand how tumor motion affects radiation therapy planning in lung cancer. It is for patients who are starting radiation treatment, possibly with chemotherapy or immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT06745882RecruitingPhase 2
Pembrolizumab for Black Patients with Advanced Lung Cancer
This study tests if the drug pembrolizumab (Keytruda), alone or with chemotherapy, works well for Black patients with advanced non-small cell lung cancer (NSCLC) who haven't had treatment yet. The goal is to see real-world results in this group.
Baltimore, MarylandAges 18 years+ - NCT05254184RecruitingPhase 1
Vaccine and immunotherapy for KRAS-mutated lung cancer
This Phase 1 study tests a KRAS-targeted vaccine combined with chemo and immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer. It aims to help the immune system recognize and fight tumors with specific KRAS mutations, and to see if the treatment is safe and effective enough to study further.
Baltimore, MarylandAges 18–100 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Baltimore, MarylandAges 18 years+ - NCT07140315RecruitingPhase 1
DK222 study for lung and bladder cancer
This trial tests a new imaging drug, DK222, to see how well it works in people with non-small cell lung cancer or bladder cancer who are about to start immunotherapy. It may help doctors see if the treatment is reaching the right targets.
Baltimore, MarylandAges 18 years+ - NCT07327489Recruiting
Live tumor biopsy study to predict immunotherapy response
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
Frederick, MarylandAges 18 years+ - NCT07190248RecruitingPhase 3
Calderasib plus other treatments for advanced non-small cell lung cancer
This trial tests a new drug called calderasib (MK-1084) combined with other treatments for people with advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination works better than current options.
Fredericksburg, VirginiaAges 18 years+ - NCT07513376RecruitingPhase 3
Adjuvant vaccine plus immunotherapy for high-risk early lung cancer
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
Fredericksburg, VirginiaAges 18 years+ - NCT06498635RecruitingPhase 3
Immunotherapy after surgery for lung cancer with no remaining cancer
This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.
Fredericksburg, VirginiaAges 18 years+
Hear when a new Lung Cancer (NSCLC) trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Lung Cancer (NSCLC) trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting lung cancer (nsclc) studies listed above.
- Hematology Oncology Associates of Fredericksburg · 3 studies
- Johns Hopkins University · 3 studies
- University of Maryland/Greenebaum Cancer Center · 2 studies
- Exelixis Clinical Site #14
- Frederick Health Hospital
- Medstar Franklin Square
- MedStar Franklin Square Medical Center
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
What taking part in a lung cancer (nsclc) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there lung cancer (nsclc) clinical trials near Washington, D.C.?
- Yes. We're currently tracking 157 recruiting lung cancer (nsclc) studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer (nsclc) study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer (nsclc) studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.